Public Release: 

Cardiac cells integrated into microneedle patches to treat heart attack

Cardiac cell-integrated microneedle patch for treating myocardial infarction

American Association for the Advancement of Science

IMAGE

IMAGE: A cardiac cell-integrated microneedle patch (blue) on an injured heart for repair. view more 

Credit: Ke Cheng/Zhen Gu

Scientists seeking to improve cell-based treatment options for heart attack survivors have engineered a patch that can better integrate therapeutic cells into viable heart tissue. The patch features an arrangement of prickly microneedles to "communicate" between the therapeutic cells and the injured heart, a task that has not yet been accomplished in an internal organ. When tested in rats and pigs that suffered an acute heart attack, the patch promoted healing by boosting the development of heart tissue, reducing scar size and increasing cardiac functions. These results suggest this cardiac stromal cell (CSC) patch may be a promising form of cardiac therapy in humans, following further tests. More than 600,000 people in the U.S. suffer a heart attack each year and 36% of survivors have an increased risk of developing heart failure in the future. Cell-based therapy has been used to improve treatment options for survivors, but so far, cell retention rate has been low in many delivery routes. To overcome this hurdle, Junnan Tang and colleagues created a microneedle (MN) patch for therapeutic heart regeneration. Its biocompatible needles can penetrate the skin and serve as communication channels between the patch and the heart, feeding CSCs from the patch to the injured area for repair. In a rat model of heart attack, the researchers placed a 0.5-centimeter by 0.5-centimeter MN-CSC patch containing rat CSCs directly onto the damaged area of the rat's heart during open heart surgery. The patch treatment reduced cardiac cell death and promoted growth of myocytes - cells found in muscle tissue of the heart - as well as the development of new heart tissue. The authors further validated their device in a pig - an animal that has similar blood flow features to humans - and this test confirmed the safety and biocompatibility of the MN-CSC patch. According to Tang et al., future work should focus on less invasive ways to deliver the patch, rather than during open heart surgery.

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.